Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12392245 | 0.91 | NR1H2 (0.55) | NR1H2NR1H3L3MBTL1HTTMAPT | |
| SCHEMBL2345886 | 0.90 | NR1H2 (0.69) | NR1H2NR1H3 | |
| SCHEMBL997425 | 0.89 | NR1H2 (0.60) | NR1H2NR1H3L3MBTL1HTTMAPT | |
| SCHEMBL995440 | 0.89 | NR1H2 (0.60) | NR1H2NR1H3L3MBTL1HTTMAPT | |
| SCHEMBL995268 | 0.88 | NR1H2 (0.60) | NR1H2NR1H3L3MBTL1HTTMAPT | |
| SCHEMBL994870 | 0.86 | NR1H2 (0.55) | NR1H2NR1H3L3MBTL1HTT | |
| SCHEMBL993843 | 0.86 | NR1H2 (0.55) | NR1H2NR1H3L3MBTL1HTT | |
| SCHEMBL997060 | 0.86 | NR1H2 (0.55) | NR1H2NR1H3L3MBTL1HTT | |
| SCHEMBL12392252 | 0.83 | NR1H2 (0.61) | NR1H2NR1H3HTTMAPT | |
| SCHEMBL995363 | 0.83 | NR1H2 (0.56) | NR1H2NR1H3HTTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008306-B2 | Quinoline compounds | KOWA COMPANY, LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2272843-A1 | QUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100016327-A1 | QUINOLINE COMPOUNDS | KOWA COMPANY, LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016327-A1 | QUINOLINE COMPOUNDS | NR1H2, NR1H3, LDLR | NR1H2 1/4885NR1H3 2/4885L3MBTL1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.